FCGR2A and lymphoma: A systematic comparison revealed that in terms of tumor therapy, whole anti-FcγR-expressing tumor cells were most suitable for DC loading not only in comparison to unmodified lymphoma cells but also to soluble Id proteins even when these were engineered to be redirected to FcγR.